< Back to previous page
Researcher
Thierry Vandendriessche
- Keywords (Vrije Universiteit Brussel):Medicine, Applied biological sciences, biotechnology
- Disciplines (Vrije Universiteit Brussel):Hematology, Computational transcriptomics and epigenomics, Neurological and neuromuscular diseases, Cancer therapy, Cardiology
- Disciplines (KU Leuven):Gene and molecular therapy
Affiliations
- Division of Gene Therapy & Regenerative Medicine (Research group)
Responsible
From19 Apr 2011 → Today - Basic (bio-) Medical Sciences (Department)
Member
From8 Apr 2019 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → Today - Cell Biology and Histology (Department)
Member
From1 Oct 2010 → 31 Dec 2013 - Department of Bio-engineering Sciences (Department)
Member
From1 Feb 2010 → 28 Feb 2010 - Immunology and Microbiology (Department)
Member
From1 Oct 2007 → 30 Sep 2010 - Department of Bio-engineering Sciences (Department)
Member
From1 Feb 2007 → 30 Sep 2010 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2003 → 30 Sep 2004 - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → Today - Department of General Biology (Research group)
Member
From1 Oct 1990 → 30 Sep 1994
Projects
1 - 3 of 3
- Development of stem cell-based gene therapy for Duchenne muscular dystrophy.From27 Sep 2010 → 16 Jun 2016Funding: FWO fellowships
- Role of microRNA in controlling hepatic carcinogeneis: in vivo validation, mechanisms and therapeutic implications.From1 Jan 2010 → 31 Dec 2015Funding: FWO research project
- Role of micro-RNA in cardiac hypertrophy: fundamental and therapeutic implications.From1 Jan 2009 → 31 Dec 2011Funding: FWO research project
Publications
1 - 10 of 140
- Hemophilia Gene Therapy: The End of the Beginning?(2023)
Authors: Thierry Vandendriessche
Pages: 782 - 792 - First hemophilia B gene therapy approved: More than two decades in the making(2023)
Authors: Thierry Vandendriessche
Pages: 1 - 2 - Hemophilia "A" gene therapy: Lost in translation(2022)
Authors: Thierry Vandendriessche
Pages: 3508 - 3509 - First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy(2022)
Authors: Thierry Vandendriessche
Pages: 3335 - 3336 - Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy(2022)
Authors: Thierry Vandendriessche
Pages: 3155 - 3175 - Should patients with haemophilia receive gene therapy?(2022)
Authors: Thierry Vandendriessche
Pages: e722 - e723 - Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders(2022)
Authors: Thierry Vandendriessche
- Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes(2022)
Authors: Thierry Vandendriessche
Pages: 75 - 91 - The RNA World: The Best of Times, the Worst of Times(2021)
Authors: Thierry Vandendriessche
Pages: 975 - 977 - Dose-Dependent Microdystrophin Expression Enhancement in Cardiac Muscle by a Cardiac-Specific Regulatory Element(2021)
Authors: Thierry Vandendriessche, Marinee Chuah
Pages: 1138 - 1146
Patents
1 - 1 of 1